Pharmacogenetics of efficacy and safety of HCV treatment in HCV-HIV coinfected patients: significant associations with IL28B and SOCS3 gene variants by Vidal Francesc, López-Dupla Miguel, Laguno Montserrat, Veloso Sergi, Mallolas Josep, Murillas Javier, Cifuentes Carmen, Gallart Lluis, Auguet Teresa, Sampériz Gloria, Payeras Antoni, Hernandez Pilar, Arnedo Mireia, Gatell Josep Ma, Richart Cristóbal in PloS one (2012). PubMed

Abstract

This was a safety and efficacy pharmacogenetic study of a previously performed randomized trial which compared the effectiveness of treatment of hepatitis C virus infection with pegylated interferon alpha (pegIFNalpha) 2a vs. 2b, both with ribavirin, for 48 weeks, in HCV-HIV coinfected patients.

[ hide abstract ]

Discussed In Paper

Variant Annotations

Sign in to see variant annotations.